820971-67-3

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 3-(methoxy(methyl)carbamoyl)azetidine-1-carboxylate is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 3-(methoxy(methyl)carbamoyl)azetidine-1-carboxylate is used as a building block for the development of pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of new drug candidates.
Used in Pharmaceutical Development:
Tert-butyl 3-(methoxy(methyl)carbamoyl)azetidine-1-carboxylate is utilized in the development of pharmaceuticals due to its potential to be incorporated into molecules with therapeutic properties. Its reactivity and functional groups make it a promising candidate for creating novel medications.
Used in Agrochemical Development:
Similarly, in agrochemical development, tert-butyl 3-(methoxy(methyl)carbamoyl)azetidine-1-carboxylate is used for its potential to be part of molecules with pesticidal or herbicidal properties, contributing to the creation of new agrochemical products for agricultural applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 142253-55-2 1-(t-butyloxycarbonyl)-azetidine-3-carboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 870761-78-7 tert-butyl 3-[(5-bromopyridin-2-yl)carbonyl]azetidine-1-carboxylate 
• 820971-68-4 tert-butyl 3-(3,5-difluorophenyl)azetidine-1-carboxylate 
• 1225652-50-5 1-tert-butoxycarbonyl-3-cyclohexanecarbonylazetidine 
• 206446-44-8 tert-butyl 3-benzoylazetidine-1-carboxylate 
• 1246495-06-6 tert-butyl 3-((2,4-dichlorobenzamido)(phenyl)methyl)azetidine-1-carboxylate 
• 1246495-09-9 tert-butyl 3-((2,4-dichlorobenzamido)(pyridin-1-yl)methyl)azetidine-1-carboxylate 
• 1402238-44-1 tert-butyl 3-(2-phenylacetyl)azetidine-1-carboxylate 
• 1138331-90-4 tert-butyl 3-(1-hydroxyethyl)azetidine-1-carboxylate 
• 960402-24-8 tert-butyl 3-(4-bromobenzoyl)azetidine-1-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS

Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R 1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of these dihydroisoxazole compounds and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

NEW HETEROCYCLIC COMPOUNDS

The invention provides new heterocyclic compounds having the general formula (IA) wherein A, L, X, Y, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES

The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

Aromatic cycloamines derivative and application in multi-target antidepressant medicine

The invention discloses an aromatic cycloamines derivative and an application in multi-target antidepressant medicine. The aromatic cycloamines derivative has inhibitory activity on 5-HT reuptake, NEreuptake and DA reuptake, is a novel compound of a 5-HT/

NOVEL IMIDAZOLE DERIVATIVES

Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salts thereof, that exhibit antimicrobial activity against gram-negative bacteria including multi-drug resistant strains and that are useful in the treatment of bacterial infections.

SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplasia syndrome (MDS) and diabetes.

ISOQUINOLONES AS BTK INHIBITORS

The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton’ s tyrosine kinase (Btk), and for treating disorders mediated thereby.